An early review conducted by The Food and Drug Administration (FDA) of Sanofi’s combination diabetes drug iGlarLixi is raising issues related to efficacy.
Janssen Phase 3 data presented for the first time at Digestive Disease Week 2016 showed that a significantly greater proportion of adult patients with moderate to severe Crohn's disease receiving Stelara (ustekinumab) subcutaneous (SC) maintenance therapy were in clinical remission at one year.
New results from a Phase 1 clinical trial that tested Eli Lilly’s investigational CDK4/6 inhibitor indicates that abemaciclib is likely in line to become an FDA-approved CDK4/6 inhibitor.
The recent legalization of cannabis for medical purposes in some US states has reinvigorated the debate over cannabis in Germany.
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
The spread of yellow fever is a global health threat.
“Cure” is a word that’s dominated the rhetoric in the war on cancer for decades.
Analyses remain ongoing and will be the subject of future publications and presentations.
All three firms aim to contribute to the enhancement of health and welfare of people around the world through creating innovative medicine.
The technology addresses the profound challenge of drug resistance among HIV-infected patients in resource-poor areas.
The group is now working with US clinical stage biotechnology company PharmaCyte Biotech to commercialize the research.
This decision was made less than a year after regulatory approvals.
This drug is projected to be an important source of revenue for Novo Nordisk.
The mistaken activation of certain cell-surface receptors contributes to a variety of human cancers.
France's health minister presented a plan on Monday to tighten the rules regarding human drug trials following an experimental test that killed a volunteer in January.